This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

NICE guidance - beta interferon for the treatment of multiple sclerosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Glatiramer acetate is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and
    • the company provides it according to the commercial arrangement

  • Interferon beta-1a is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and
    • the companies provide it according to commercial arrangement

  • Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis, only if:
    • the person has relapsing-remitting multiple sclerosis and has had 2or more relapses within the last 2 years or
    • the person has secondary progressive multiple sclerosis with continuing relapses
    • and the company provides it according to the commercial arrangement.

Reference:

(1) NICE (June 2018). Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Web: www.nice.org.uk

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.